| scholarly article | Q13442814 |
| P50 | author | Sattva S Neelapu | Q91522188 |
| P2093 | author name string | Kim-Anh Do | |
| Varsha Gandhi | |||
| Qingshan Yang | |||
| Lisa S Chen | |||
| Min Jin Ha | |||
| P2860 | cites work | Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation | Q24312168 |
| Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. | Q38237619 | ||
| Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. | Q39151631 | ||
| Parallel and independent regulation of interleukin-3 mRNA turnover by phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase | Q39460786 | ||
| CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability | Q39642145 | ||
| The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia | Q39722770 | ||
| A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1. | Q39922852 | ||
| Establishment and characterization of a new mantle cell lymphoma cell line, Mino | Q40717061 | ||
| SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling | Q40919280 | ||
| Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival | Q41868647 | ||
| PI3 kinase signals BCR-dependent mature B cell survival | Q41886641 | ||
| Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies | Q42320922 | ||
| Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer | Q47372605 | ||
| Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK/MAPK signal transduction pathway | Q47400542 | ||
| FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. | Q55068271 | ||
| p110δ, a novel phosphoinositide 3-kinase in leukocytes | Q24314825 | ||
| Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma | Q24613755 | ||
| The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation | Q24616946 | ||
| The PI3K pathway as drug target in human cancer | Q24632283 | ||
| Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma | Q26865645 | ||
| Targets of B-cell antigen receptor signaling: the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase-3 signaling pathway and the Rap1 GTPase | Q28141951 | ||
| Characterization of 4 mantle cell lymphoma cell lines | Q28189659 | ||
| Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice | Q28215433 | ||
| PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma | Q28256448 | ||
| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia | Q28306347 | ||
| Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha | Q28616168 | ||
| Ras, PI(3)K and mTOR signalling controls tumour cell growth | Q29614734 | ||
| PI3K pathway alterations in cancer: variations on a theme | Q29615530 | ||
| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma | Q30371806 | ||
| Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma | Q33413834 | ||
| PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma | Q33690142 | ||
| Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia | Q34009003 | ||
| Quantification of PtdIns(3,4,5)P(3) dynamics in EGF-stimulated carcinoma cells: a comparison of PH-domain-mediated methods with immunological methods | Q34041606 | ||
| Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals | Q34184717 | ||
| Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. | Q34443608 | ||
| A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). | Q34663617 | ||
| The development of mature B lymphocytes requires the combined function of CD19 and the p110δ subunit of PI3K | Q34729503 | ||
| Perspectives on the nature of BCR-mediated survival signals | Q35807570 | ||
| Oncogenic PI3K deregulates transcription and translation | Q36337966 | ||
| Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma. | Q36649225 | ||
| P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse | Q36709839 | ||
| Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations | Q36742629 | ||
| The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways. | Q37200384 | ||
| Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells | Q37414714 | ||
| PIKKing on PKB: regulation of PKB activity by phosphorylation | Q37419888 | ||
| CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. | Q37625487 | ||
| Role of PI3K in the generation and survival of B cells | Q37781389 | ||
| Targeting pathological B cell receptor signalling in lymphoid malignancies | Q38085501 | ||
| New insights into pre-BCR and BCR signalling with relevance to B cell malignancies | Q38123936 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell growth | Q189159 |
| P304 | page(s) | 181-192 | |
| P577 | publication date | 2016-06-24 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. | |
| P478 | volume | 23 |
| Q38611244 | B cell receptor signaling regulates metabolism in Chronic Lymphocytic Leukemia |
| Q39065374 | Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). |
| Q39226787 | Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia |
| Q58567814 | Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma |
| Q46318389 | Recent therapeutic advances in chronic lymphocytic leukemia |
| Q90633546 | Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia |
Search more.